Cargando…

Synchronal pulmonary sarcomatoid carcinoma and lung adenocarcinoma EML4-ALK fusion: A case report

Pulmonary sarcomatoid carcinoma (PSC) is a rare form of poorly differentiated non-small-cell lung cancer that is prone to distant metastases. PSC is therapeutically challenging, with low sensitivity to conventional radiotherapy and a poor overall prognosis. The present study reported on the case of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Mingting, Gong, Yifan, Cheng, Yun, Yang, Lei, Wang, Wenhui, Lei, Xiaolin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2022
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9434725/ https://www.ncbi.nlm.nih.gov/pubmed/36072009 http://dx.doi.org/10.3892/ol.2022.13463

Ejemplares similares

EML4-ALK fusion gene in non-small cell lung cancer
por: Lei, Yu, et al.
Publicado: (2022)

Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression
por: Zhang, Xuchao, et al.
Publicado: (2010)

Poor prognosis of pulmonary sarcomatoid carcinoma with KRAS mutation and ALK fusion
por: Chen, Fangmin, et al.
Publicado: (2019)

Concomitant novel ALK-SSH2, EML4-ALK and ARID2-ALK, EML4-ALK double-fusion variants and confer sensitivity to crizotinib in two lung adenocarcinoma patients, respectively
por: Tao, Hong, et al.
Publicado: (2022)

Genomic Profiling Reveals Synchronous Bilateral Lung Adenocarcinomas With Distinct Driver Alterations of EML4-ALK or TPM3-ROS1 Fusion: A Case Report
por: Tan, Benxu, et al.
Publicado: (2019)

A case of lung adenocarcinoma harboring EGFR mutation and EML4-ALK fusion gene
por: Tanaka, Hisashi, et al.
Publicado: (2012)

The Prevalence of the EML4-ALK Fusion Gene in Cytology Specimens from Patients with Lung Adenocarcinoma
por: Heriyanto, Didik S., et al.
Publicado: (2020)

Novel NLRC4‐ALK and EML4‐ALK double fusion mutations in a lung adenocarcinoma patient: A case report
por: Wu, Xueqian, et al.
Publicado: (2020)

A rare double ALK fusion variant EML4-ALK and CDK15-ALK in lung adenocarcinoma and response to crizotinib: A case report
por: Guo, Jun, et al.
Publicado: (2020)

Thyroid metastasis from lung adenocarcinoma with EML4-ALK rearrangement
por: Kawamoto, Hironori, et al.
Publicado: (2016)

Dual drive coexistence of EML4‐ALK and TPM3‐ROS1 fusion in advanced lung adenocarcinoma
por: Zhu, You‐cai, et al.
Publicado: (2017)

A case of synchronous bilateral lung cancers: EML4-ALK positive adenocarcinoma in the right lung and adenocarcinoma in situ (the former bronchioloalveolar carcinoma) in the left lung
por: Matsuda, Ikuo, et al.
Publicado: (2013)

Metastatic pulmonary carcinoids with EML4-ALK fusion response to ALK inhibitors: two case reports and review of literature
por: Lei, Xi, et al.
Publicado: (2022)

CRKL mediates EML4-ALK signaling and is a potential therapeutic target for ALK-rearranged lung adenocarcinoma
por: An, Rong, et al.
Publicado: (2016)

Clinical and epidemiological study of EGFR mutations and EML4-ALK fusion genes among Indian patients with adenocarcinoma of the lung
por: Doval, DC, et al.
Publicado: (2015)

Clinicopathological features of younger (aged ≤ 50 years) lung adenocarcinoma patients harboring the EML4‐ALK fusion gene
por: Kometani, Takuro, et al.
Publicado: (2018)

Identification of EML4-ALK as an alternative fusion gene in epithelioid inflammatory myofibroblastic sarcoma
por: Jiang, Quan, et al.
Publicado: (2017)

EML4-ALK Fusion Gene in Korean Non-Small Cell Lung Cancer
por: Jin, Guang, et al.
Publicado: (2012)

Atypical Lung Carcinoid With EML4/ALK Fusion Detected With Circulating Tumor DNA
por: Gococo-Benore, Denise A, et al.
Publicado: (2022)

Alectinib treatment response in lung adenocarcinoma patient with novel EML4‐ALK variant
por: Song, Peng, et al.
Publicado: (2018)

Case Report: A Novel Non-Reciprocal ALK Fusion: ALK-GCA and EML4-ALK Were Identified in Lung Adenocarcinoma, Which May Respond to Alectinib Adjuvant-Targeted Therapy
por: Zhai, Xiaoqian, et al.
Publicado: (2022)

EML4–ALK fusion transcript is not found in gastrointestinal and breast cancers
por: Fukuyoshi, Y, et al.
Publicado: (2008)

EML4-ALK-Positive Pulmonary Adenocarcinoma with an Unusual Metastatic Pattern: A Case Report
por: Diem, Stefan, et al.
Publicado: (2013)

Lung adenocarcinoma harboring complex EML4-ALK fusion and BRAF V600E co-mutation responded to alectinib
por: Guo, Weihong, et al.
Publicado: (2022)

Pulmonary Sarcomatoid Carcinoma with ALK Rearrangement: Frequency, Clinical-Pathologic Characteristics, and Response to ALK Inhibitor()
por: Chen, Xinru, et al.
Publicado: (2017)

Bilateral breast adenocarcinomas with EML4–ALK fusion in a patient with multiple metastases successfully treated with crizotinib: is lung the primary site?
por: Liu, Chao, et al.
Publicado: (2016)

Targeting EML4-ALK gene fusion variant 3 in thyroid cancer
por: Aydemirli, Mehtap Derya, et al.
Publicado: (2021)

Case report: Complete pathological admission in N3 unresectable locally advanced lung adenocarcinoma with a novel INTS10-ALK and EML4-ALK fusion after neoadjuvant crizotinib
por: Zhai, Xiaoqian, et al.
Publicado: (2023)

The Author Response: EML4-ALK Fusion Gene in Korean Non-Small Cell Lung Cancer
por: Park, Jae Yong
Publicado: (2012)

Detection of EML4-ALK in Lung Adenocarcinoma Using Pleural Effusion with FISH, IHC, and RT-PCR Methods
por: Liu, Leilei, et al.
Publicado: (2015)

Alternative Treatment Options to ALK Inhibitor Monotherapy for EML4-ALK-Driven Lung Cancer
por: Papageorgiou, Savvas, et al.
Publicado: (2022)

Correlation between EML4-ALK, EGFR and clinicopathological features based on IASLC/ATS/ERS classification of lung adenocarcinoma
por: Wang, Hongyan, et al.
Publicado: (2018)

Endometrial cancer with an EML4-ALK rearrangement
por: Craig, Jeffrey W., et al.
Publicado: (2018)

Clinicopathological Characteristics of Patients with Non-Small-Cell Lung Cancer Who Harbor EML4-ALK Fusion Gene: A Meta-Analysis
por: Zhao, Fengzhi, et al.
Publicado: (2015)

Molecular Anatomy of the EML4-ALK Fusion Protein for the Development of Novel Anticancer Drugs
por: Cheon, So Yeong, et al.
Publicado: (2023)

Endobronchial Metastases in Lung Cancer Harboring EML4-ALK Rearrangement
por: Ijichi, Miharu, et al.
Publicado: (2022)

Vulnerability of drug‐resistant EML4‐ALK rearranged lung cancer to transcriptional inhibition
por: Paliouras, Athanasios R, et al.
Publicado: (2020)

Letter to the Editor: Detection of EML4-ALK and Other ALK Fusion Genes in Lung Cancer: A Lesson from the Leukemia Fusion Gene Analysis and Future Application
por: Park, Tae Sung, et al.
Publicado: (2012)

Response to erlotinib in a patient with lung adenocarcinoma harbouring the EML4-ALK translocation: A case report
por: ALÌ, GRETA, et al.
Publicado: (2015)

EML4-ALK Rearrangement as a Mechanism of Resistance to Osimertinib in Metastatic Lung Adenocarcinoma: A Case Report
por: von Buttlar, Xinyu, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_68tep852rdqkstsriknpb04cso